Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490406 | PMC |
http://dx.doi.org/10.3389/fphar.2022.1012890 | DOI Listing |
Front Pharmacol
September 2022
Department of Pathology, University at Buffalo, Buffalo, NY, United States.
Am J Kidney Dis
December 2019
University of British Columbia Canada, Vancouver, BC.
Front Endocrinol (Lausanne)
July 2019
Department of Pathophysiology, Faculty of Pharmacy, Medical University of Gdansk, Gdańsk, Poland.
Int Heart J
July 2019
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Among strategies for both the prevention and treatment of renal disease, reduction of uremic toxins and bacterial lipopolysaccharides that activates toll-like receptors and improvement in the composition of the microbiome represent valuable and clinically proven approaches. Dietary components-specifically soluble and insoluble prebiotic fibers; phytochemicals such as curcumin, berberine, epigallocatechin gallate, and withanolides that modulate gut immune function and improve detoxification of uremic toxins; and supplemental, clinically tested probiotics-constitute a family of therapeutics that can positively affect patients. In addition, the bidirectional relationship of the microbiome to kidney disease is an important concept in designing a personalized approach to the management of kidney disease, especially with regard to its relationship to cardiovascular disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!